iNtRON Biotechnology Past Earnings Performance
Past criteria checks 0/6
iNtRON Biotechnology's earnings have been declining at an average annual rate of -29.5%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been declining at an average rate of 12.4% per year.
Key information
-29.5%
Earnings growth rate
-30.4%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -12.4% |
| Return on equity | -9.1% |
| Net Margin | -90.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt
May 03
We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability
Mar 24Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?
Feb 28iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?
Jan 31
iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet
Jan 05What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You
Dec 10iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years
Nov 26Revenue & Expenses Breakdown
How iNtRON Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 9,422 | -8,518 | 4,573 | 3,057 |
| 31 Dec 23 | 9,585 | -9,695 | 4,946 | 3,174 |
| 30 Sep 23 | 8,302 | -9,560 | 4,848 | 3,072 |
| 30 Jun 23 | 9,460 | -8,652 | 5,666 | 3,057 |
| 31 Mar 23 | 10,070 | 5,372 | 6,804 | 3,183 |
| 31 Dec 22 | 14,007 | 5,712 | 6,796 | 3,312 |
| 30 Sep 22 | 19,681 | 8,015 | 6,716 | 3,086 |
| 30 Jun 22 | 24,569 | 11,708 | 6,548 | 3,598 |
| 31 Mar 22 | 29,587 | 7,149 | 6,872 | 3,681 |
| 31 Dec 21 | 29,308 | 9,728 | 7,043 | 3,553 |
| 30 Sep 21 | 33,002 | 14,948 | 7,585 | 4,229 |
| 30 Jun 21 | 32,293 | 14,948 | 7,611 | 3,890 |
| 31 Mar 21 | 47,899 | 16,886 | 6,593 | 3,634 |
| 31 Dec 20 | 45,433 | 14,948 | 6,192 | 3,489 |
| 30 Sep 20 | 35,831 | 7,677 | 5,278 | 3,082 |
| 30 Jun 20 | 30,683 | 2,915 | 5,233 | 2,843 |
| 31 Mar 20 | 9,851 | -3,396 | 4,944 | 2,766 |
| 31 Dec 19 | 8,347 | -3,187 | 4,836 | 2,252 |
| 30 Sep 19 | 19,952 | 10,876 | 5,806 | 2,382 |
| 30 Jun 19 | 19,997 | 9,268 | 5,728 | 2,922 |
| 31 Mar 19 | 19,988 | 9,739 | 5,527 | 3,026 |
| 31 Dec 18 | 20,584 | 8,711 | 5,684 | 3,660 |
| 30 Sep 18 | 9,991 | -7,018 | 4,624 | 4,033 |
| 30 Jun 18 | 10,345 | -2,844 | 4,798 | 3,871 |
| 31 Mar 18 | 10,915 | -10,056 | 4,926 | 3,699 |
| 31 Dec 17 | 10,963 | -8,734 | 4,859 | 3,501 |
| 30 Sep 17 | 11,000 | -5,271 | 4,993 | 5,085 |
| 30 Jun 17 | 10,959 | -5,448 | 4,920 | 4,218 |
| 31 Mar 17 | 10,296 | -2,146 | 4,942 | 3,727 |
| 31 Dec 16 | 10,222 | -2,252 | 4,858 | 3,106 |
| 31 Dec 15 | 11,835 | 1,558 | 4,387 | 428 |
| 30 Sep 13 | 8,568 | 106 | 4,390 | 0 |
Quality Earnings: A048530 is currently unprofitable.
Growing Profit Margin: A048530 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A048530 is unprofitable, and losses have increased over the past 5 years at a rate of 29.5% per year.
Accelerating Growth: Unable to compare A048530's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A048530 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A048530 has a negative Return on Equity (-9.15%), as it is currently unprofitable.